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Pancreatic beta cells uniquely synthetize, store, and release insulin. Specific molecular,
functional as well as ultrastructural traits characterize their insulin secretion properties
and survival phentoype. In this review we focus on human islet/beta cells, and describe
the changes that occur in type 2 diabetes and could play roles in the disease
as well as represent possible targets for therapeutical interventions. These include
transcription factors, molecules involved in glucose metabolism and insulin granule
handling. Quantitative and qualitative insulin release patterns and their changes in type
2 diabetes are also associated with ultrastructural features involving the insulin granules,
the mitochondria, and the endoplasmic reticulum.
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INTRODUCTION
The pancreatic beta cells are endocrine cells that synthetize, store, and release insulin, the
anti-hyperglycemic hormone that antagonizes glucagon, growth hormone, glucocorticosteroids,
epinephrine, and other hyperglycemic hormones, to maintain circulating glucose concentrations
within a narrow physiologic range. Beta cells have an average diameter of 10 µm, contain about 20
pg insulin per cell, and are the predominant cell type in the pancreatic islets (50–80% of all islet
endocrine cells) (Marchetti and Ferrannini, 2015). In the human pancreas, beta cell mass has been
reported to vary from 0.6 to 2.1 g, and the amount of insulin in the gland has been observed to
range from 50 to 250 ug/g (Marchetti and Ferrannini, 2015). In an adult human being, beta cells
release∼30–70 U insulin per day (mainly depending on body weight), half of which is secreted after
meals and the rest under basal conditions. The release of this hormone is regulated by a complex
network of many different triggering, potentiating or inhibiting signals, which allows the supply of
the hormone in amount, kinetics and adaptability to match the minute-by-minute variable needs
of the body (Henquin, 2005). In this article we will describe some key distinguishing molecular,
functional, and ultrastructural features of the human beta cells, with emphasis on changes occuring
in the case of type 2 diabetes.
MOLECULAR IDENTITY
Insulin expressing beta cells are the first endocrine cells to appear in the human pancreas, at 7.5–8
weeks of gestation, i.e., approximately 3 weeks after the initial formation of the dorsal and ventral
pancreatic buds (Pan and Brissova, 2014). Shortly after, glucagon and somatostatin-expressing cells
appear (gestational week 8), followed by ghrelin-expressing cells (gestational week 9; Piper et al.,
2004; Pan and Brissova, 2014). However, a few authors have reported that beta cells are detectable
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from gestational week 9 onward, whereas glucagon expressing
cells appear already at week 8 (Meier et al., 2010). In addition,
during the early fetal period, small proportions of cells may co-
express both insulin and glucagon (Meier et al., 2010; Riedel et al.,
2012).
The transcription factor NGN3 is needed to commit
progenitor cells toward an endocrine cell phenotype (Gradwohl
et al., 2000; Pan and Brissova, 2014). Expression of NGN3
peaks by the end of the first trimester and disappears at about
the 35th week of gestation. In the early (8th–11th) weeks
of gestation of the human fetal pancreas, cells co-expressing
NGN3 and PDX1, NGN3 and insulin, NGN3 and glucagon have
been observed (Lyttle et al., 2008). Additional transcriptional
regulators specifically associated with pancreatic endocrine cells
at these stages include PAX6, NKX2.2, NKX6.1, ISLET1, and
PAX4 (Lyttle et al., 2008; Sarkar et al., 2008; Jennings et al.,
2015). Also in the adult human pancreas, maintenance of beta
cell identity is associated with the presence of key transcription
factors (in particular PDX1, FOXO1, MAFA, NKX6.1), and
changes in their expression and/or localization have been
described in the islets from type 2 diabetic (T2D) individuals,
contributing to beta cell de-differentiation (i.e., the regression
to a progenitor-like state) in this disease (Talchai et al., 2012;
Guo et al., 2013; Kitamura, 2013; Rutter et al., 2015; Spijker
et al., 2015; Cinti et al., 2016; Remedi and Emfinger, 2016). In
particular, a study (Cinti et al., 2016) reported the use of a de-
differentiation score based on markers of endocrine lineage, beta
cell specific transcription factors, and the endocrine progenitor
cell marker, aldehyde dehydrogenase 1A3, to show a three- to
four-fold increase of de-differentiated cells in islets from type 2
diabetes. On the same line, other authors (Spijker et al., 2015)
have found a several fold higher frequency of cells double positive
for insulin and glucagon in the diabetic samples, together with a
5 times increase of cells that were Nkx6.1 and glucagon positive,
but insulin negative (a finding that was correlated with the
presence and extent of islet amyloidosis).
In addition to transcription factors, the expression of several
additional genes has been found to change in T2D islets
by real-time RT-PCR, compared to adult non-diabetic (ND)
samples. For instance, GLUT2 and glucokinase were found to
be downregulated in type 2 diabetic islets (Del Guerra et al.,
2005). Furthermore, changes of the expression of genes involved
in regulating cell redox balance have been shown (Marchetti
et al., 2004): NADPH oxidase was found to be increased and that
of Mn and Cu/Zn superoxide dismutases decreased in diabetic
islets, together with enhanced expression of catalase and GSH
peroxidase.
More comprehensive assessments have been performed
by studying the transcriptomic features of isolated islets by
microarray o RNA-sequencing (see also Table 1). Gunton et al.
first profiled the gene expression of islets from 7 ND and 5 T2D
individuals using oligonucletotide microarrays (Gunton et al.,
2005). Significant (p < 0.01) changes in the expression of 370
out of the 44,298 genes and ESTs examined were found, with
downregulation of several genes relevant for beta cell function,
such as HNF4, but also for glucose-sensing (including GLUT2)
and insulin-signaling. Afterwards, independent analysis of 4 ND
and 4 T2D islet preparations showed reduced expression in
T2D islets of factors implicated in mitochondrial function and
regulated exocytosis (Ostenson et al., 2006; MacDonald et al.,
2009). More recent work with 7 ND and 6 T2D islet preparations
pointed to the occurrence of changes in genes of the ubiquitin–
proteasome system (Bugliani et al., 2013), with however several
additional alterations in genes and pathways affecting many
islet cell structures and functions, from glucose metabolism and
insulin granule exocytosis to oxidative stress and cell turn-over.
Groop and his collaborators have largely contributed to this
field (Mahdi et al., 2012; Taneera et al., 2012, 2015; Fadista
et al., 2014). They originally studied islets from 54 ND to 9
T2D organ donors (Taneera et al., 2012), with the addition
of some more cases in experiments thereafter. By the use of
several integrated biosystems analysis approaches, they identified
genes such as CHL1, LRFN2, RASGRP1, PPM1K, PPP1R1A,
FAM105A, ENO2, PLCDX3, GNG5, TSPAN33, TMED6, and
PAK7 to be related to the disease associated reduction of insulin
secretion (Taneera et al., 2012; Fadista et al., 2014). In addition,
they reported that the expression of SRFP4, which encodes
secreted frizzled-related protein 4, is upregulated in T2D islets,
possibly representing a link with beta cell inflammation (Mahdi
et al., 2012). More lately, preliminary data have been presented
(Solimena et al., 2016; EASD annual meeting) obtained with islets
isolated either by enzymatic digestion from 103 organ donors
(84 ND and 19 T2D), or by laser capture microdissection from
surgical specimens of pancreatectomized patients (including
32 ND and 36 T2D individuals). Comparative transcriptomic
analysis identified 19 genes differentially expressed (FDR ≤
0.05, fold change ≥ 1.5) in T2D as compared to ND islets,
including GLUT2, ARG2, PPA1R1A; in addition, systems biology
approaches identified HNF1A, PDX1, and REST as drivers of
gene co-expression modules correlated with impaired insulin
secretion, that were enriched in 14 out of the 19 differentially
expressed genes.
TABLE 1 | Some studies reporting transcriptomic data in type 2 diabetic
(T2D) and non-diabetic (ND) islets or beta cells.
Technique T2D vs. ND References
Islet Microarray Dysregulation of 370 genes/EST Gunton et al., 2005
Focus on genes involved in
exocytosis
Ostenson et al., 2006
Focus on genes involved in
mitochondrial function
MacDonald et al., 2009
Focus on genes of the
ubiquitin-proteasome system
Bugliani et al., 2013
Global map of genes associated
with beta cell dysfunction
Taneera et al., 2012
Focus on Secreted frizzle-related
protein 4
Mahdi et al., 2012
Islet RNA seq Global genomic and
transcriptomic analysis
Fadista et al., 2014
Laser-capture
microdissected beta
cells
Almost 2,000 transcripts
dysregulated
Marselli et al., 2010
Single cell RNA seq 48 transcripts dysregulated Xin et al., 2016
75 transcripts dysregulated Segerstolpe et al., 2016
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However, islets represent an heterogeneous combination
of different endocrine cells, and efforts are being made to
identify specific beta cell features in ND and T2D humans.
By using a technique based on laser capture microdissection,
Marselli et al. studied beta cells from 10 ND to 10 T2D
organ donors (Marselli et al., 2010). Several thresholds were
employed to assess differences: with the lower confidence
bound (LCB) parameter at the cutoff of 1.2, 2,062 differentially
expressed probe sets, corresponding to 1,920 transcripts, were
identified (1,203 were upregulated and 717 downregulated in
T2D islets); with the p-value set at <0.05, 7,164 probe sets,
corresponding to 6,384 transcripts, were found to be dysregulated
in T2D islets (3,464 upregulated and 2,920 downregulated);
with a more stringent p-value (<0.01), 2,133 probe sets,
corresponding to 1,870 transcripts were different in the diabetic
samples (1,006 upregulated and 864 downregulated). Among
the differentially expressed genes, there were some linked to
glucotoxicity, oxidative stress, cell cycle, apoptosis, endoplasmic
reticulum stress, and pancreatic regeneration. In addition, the
expression of a proportion of the genes found in GWAS
studies to be associated with T2D was observed to change
in T2D islets, including IGF2BP2, TSPAN8, and HNF1B
(upregulated), and JAZF1 and SLC30A8 (downregulated).
HNF1A was also downregulated, whereas PAX6 and PDX1 (that
showed however a low signal strength) were upregulated in
the diabetic samples. Transcription factors that did not change
included NKX2-2, NKX6.1, NEUROD1, PAX4, HNF4A, NGN3,
and MAFB.
More recently, RNA-seq studies have been published using
single human pancreatic cells, obtained from islets isolated from
ND and T2D organ donors by enzymatic digestion (Xin et al.,
2016) or dissociation and FACS sorting (Segerstolpe et al., 2016).
The comparison of beta cells isolated from ND (respectively
from 12 and 6 preparations) or T2D (respectively from 6 and 4
preparations) showed that 48 (Xin et al., 2016) or 75 (Segerstolpe
et al., 2016) transcripts were differentially expressed between
control and diabetic samples. Of note, only one gene (FXYD2)
was regulated in both studies, but in opposite directions. It
is conceivable that the use of single cell RNA seq techniques
will have a rapid development in the future, including the
possibility of its use to better define cell type diversity and the
dynamics of cell development, and also provide quantitative and
comprehensive information (Kumar et al., 2017).
Therefore, in essence the beta cell is characterized, at
the molecular level, by expressing insulin since its early
embryogenesis, and a few transcription factors are key to its
maturation and maintenance of competence. Many molecules
are implicated in beta cell function and turn-over, and several
have been found to change in T2D islets and/or beta cells.
However, due to islet and beta cell heterogeneity (differences
between donors and portions of the pancreas, diverse distribution
of the islets in the pancreatic lobules, variable islet sizes,
unpredictable proportions, and location of endocrine cells in
the islets; Bonner-Weir and Aguayo-Mazzucato, 2016; Roscioni
et al., 2016; Gutierrez et al., 2017), as well as to limitations of the
available techniques, a precise molecular profiling of the “typical”
T2D beta cell is still missing.
FUNCTIONAL IDENTITY
The key role of the beta cells is to produce and secrete insulin
in a tightly regulated manner, to maintain circulating glucose
concentrations in the (narrow) physiological range (Cavaghan
and Polonsky, 2005; Henquin, 2005; Poitout et al., 2015). Of
the several physiological compounds known to stimulate insulin
secretion (Table 2), glucose is by far the most important. The
increase of insulin release in response to oral and intravenous
glucose is dose-dependent and the secretion is greater after oral
than intravenous administration. This phenomenon has been
named incretin effect (Nauck et al., 1986), and appears to be due
to the release of gastrointestinal hormones and othermechanisms
elicited by glucose in the enteric tract. The secretion of insulin by
the beta cell is dynamic. Intravenous glucose infusion determines
a biphasic insulin response, consisting of an early rapid peak
(first phase, lasting a few minutes), followed by a slower and
more prolonged increase (second phase). In addition, insulin
secretion is pulsatile (Cavaghan and Polonsky, 2005). The pulses
period is normally of 8–10 min and they superimpose on longer
fluctuations. The islets themselves are probably the “controllers”
of the high-frequency pulses, whereas the control of the lower-
frequency oscillations may be from outside the islets.
At the cellular level, glucose exerts its effects through
intermingled mechanisms that overall are now defined according
to models of stimulus-secretion coupling (Juhl and Hutton,
2004; Henquin, 2011). Glucose is both a trigger and an
amplifier of insulin secretion. As synthetized in Figure 1 (based
on: Juhl and Hutton, 2004; Cavaghan and Polonsky, 2005;
Henquin, 2005, 2011; Marchetti et al., 2008; Poitout et al.,
2015) its transport into the beta cell cytoplasm is facilitated
by glucose transporter 1 and 2 (GLUT1 and GLUT2). Then
the exose is rapidly phosphorylated by glucokinase (a high Km
isoform of hexokinase) to begin the glycolytic process. Since
glucose-6-phosphate is produced without allosteric inhibition,
glucokinase itself is the controller of the rate of glycolysis; the
enzyme is therefore considered the molecular glucose sensor
TABLE 2 | Main physiological regulators of insulin secretion.
Nutrients Glucose (Henquin, 2005)
Amino acids (Newsholme et al., 2014)
Free fatty acids (>C12) (Warnotte et al.,
1999; Morgan and Dhayal, 2009)
Ketones (Panten et al., 2013)
Hormones GLP-1 (Drucker and Nauck, 2006)
GIP (Drucker and Nauck, 2006)
CCK (Ning et al., 2015)
Glucagon (Unger, 1985)
VIP (Sanlioglu et al., 2012)
Gastrin (Rehfeld, 2011)
Secretin (Glaser et al., 1988)
PACAP (Sanlioglu et al., 2012)
Neurotransmitters Acetylcholine (Gilon and Henquin, 2001)
Norepinephrine (Straub and Sharp, 2012)
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FIGURE 1 | Key mechanisms of glucose-induced insulin secretion.
Glucose enters the beta cell rapidly through specific glucotransporters and is
phosphorylated by glucokinase; this step regulates metabolic flux through
glycolysis. After pyruvate has entered the mitochondria, reducing equivalents
are produced by the tricarboxylic acid cycle. ATP is then generated and the
augmented ATP/ADP ratio causes the closure of the ATP-sensitive K+ (KATP)
channels in the membrane. The successive depolarization of the plasma
membrane leads to influx of extracellular Ca2+ and activation of exocytosis.
Additional products generated in the mitochondria may also affect insulin
release.
that regulates insulin release from the beta cell. Glycolysis ends
with the production of pyruvate, the three-carbon molecule
that enters the mitochondria to be oxidated. Pyruvate is first
converted by pyruvate kinase to acetyl-CoA, that in turn reacts
with oxalocetate in a reaction catalyzed by citrate synthase to
obtain citrate, a component of the tricarboxylic acid (TCA)
cycle. Activation of this cycle leads to the generation of NADH
and FADH2,and these reducing equivalents are employed in
the production of ATP in the electron transport chain. The
ATP produced in the mitochondria is then transported to
the cytoplasm by the adenine nucleotide translocator (ANT).
The augmented cytosolic ATP levels determine the closure of
the KATP channels, reduction of K
+ conductance and plasma
membrane depolarization. Therefore, the KATP channels couple
the metabolic activity of the beta cell to the electrical state.
In turn, depolarization of the plasma membrane induces the
opening of L-type voltage-dependent Ca2+ channels, causing a
rapid depolarization to a plateau potential with superimposed
bursts of Ca2+ potentials. Ca2+ influx into the beta cell cytoplasm
mobilizes the insulin granules, followed by membrane docking
and exocytosis.
As mentioned above, glucose can also amplify the secretion
of insulin, which means that products of glucose metabolism
potentiate the exocytosis of the insulin granules without
any further increase of cytosolic Ca2+ concentrations (Juhl
and Hutton, 2004; Henquin, 2005, 2011). The mechanisms
responsible of the amplifying pathway are not clearly defined
yet, but possible mediators include metabolites produced in the
mitochondria during glucose metabolism.
In addition to glucose, several other compounds affect insulin
secretion from the beta cell (Table 2). A few aminoacids, either
alone or in combination, induce or potentiate the release of
the hormone by metabolic mechanisms, biophysical processes,
or both (Newsholme et al., 2014). Some of them (such as
leucine and glutamate) are metabolized in themitochondria, thus
fueling the TCA cycle. Arginine, instead, depolarizes the plasma
membrane after it is transported into the cytoplasms, due to
its positive charges. This depolarization activates the voltage-
dependent Ca2+ channels which in turn permits the entry of
this ion, leading to the successive insulin granule exocytosis.
Free fatty acids can stimulate insulin release by either acting as
metabolic substrates (modulating the oxidation of fuel molecules
in the mitochondria) and/or by binding to specific G-protein
coupled receptors (GPRs, in particular GPR40 and also GPR119
and GPR120) that are expressed on the membrane of beta cells
(Warnotte et al., 1999; Morgan and Dhayal, 2009). Finally, the
GPRs system is also involved in the modulation of insulin release
induced by hormones and neurotransmitters. In this regard,
the role of the incretin hormone GLP-1 has been specifically
and extensively investigated, mainly in consideration that the
GLP-1 system has become a target for the treatment of type 2
diabetes (Drucker and Nauck, 2006). GLP-1 is secreted from the
enteroendocrine L-cells after nutrient ingestion and potentiate
insulin release glucose dependently. GLP-1 mechanisms of action
on insulin secreting cells include activation of adenylate cyclase as
well as production of IP-3 and DAG. The consequent activation
of PKA-dependent and independent processes, leads, mainly
through Epac2 action and the PKA-mediated phosphorylation
of several substrates, to increased insulin granule movement
and ion channels activity (Doyle and Egan, 2007). Additional
regulators of insulin-release are reported in Table 2 (Gilon and
Henquin, 2001; Glaser et al., 1988; Newsholme et al., 2014; Ning
et al., 2015; Panten et al., 2013; Rehfeld, 2011; Sanlioglu et al.,
2012; Straub and Sharp, 2012; Unger, 1985).
In type 2 diabetes there are several quantitative and qualitative
alterations of insulin secretion (Cavaghan and Polonsky, 2005;
Henquin, 2005; Marchetti and Ferrannini, 2015). Usually
reported changes include blunted or absent first phase insulin
release to intravenous glucose, delayed and/or reduced responses
to the ingestion of a mixed meal, and over the years, decreased
second phase release and secretion to non-glucose stimuli.
In addition, alterations of pulsatile patterns and increased
proinsulin release have been described. Studies with isolated
human islets have allowed direct characterization of some
features of insulin release in T2D ex-vivo. In early experiments
it was shown that glucose-induced insulin release was decreased
with T2D islets, whereas the secretory response to combined L-
leucine and L-glutamine stimulation was less markedly impaired
(Fernandez-Alvarez et al., 1994). In another study, islets prepared
from 9 ND and 8 T2D donors were evaluated ex-vivo by the
perifusion technique (Deng et al., 2004). The Authors found
that the diabetic islets secreted lower amount of insulin upon
stimulation with increasing glucose concentrations and also
showed a higher threshold needed to initiate insulin release.
These findings were essentially confirmed in an independent
article from a different group (Marchetti et al., 2004). Lately,
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insulin secretion was measured in ND and T2D islets upon
challenge with glucose, glibenclamide and arginine (Del Guerra
et al., 2005). In this study, the diabetic islets released significantly
less insulin than control islets in response to glucose and also
during glibenclamide and arginine stimulation; however, they
secreted more insulin in response to non-glucose stimuli than in
response to the exose, suggesting more marked beta cell defects
when glucose is the secretagogue compound. As mentioned
earlier in the present article, the three tested secretagogues
(glucose, glibenclamide, and arginine) induce insulin secretion
through different mechanisms (Juhl and Hutton, 2004; Cavaghan
and Polonsky, 2005; Henquin, 2005, 2011; Marchetti et al., 2008;
Poitout et al., 2015): glucose needs to enter the beta cell and
be metabolized to produce ATP, whereas glibenclamide causes
insulin secretion by binding to the KATP channels and determong
their closure; finally, arginine enters the beta cell through the
CAT 2A cationic aminoacid transporter and induces excess of
positive charges with subsequent depolarization of the plasma
membrane. It is therefore possible that specific defects of glucose
handling may be present in the T2D beta cell. Consistent with
this, the expression of glucose transporters has been found to
be lower in T2D than ND islets (Gunton et al., 2005; Taneera
et al., 2012; Solimena et al., 2016; EASD annual meeting). More
importantly, several evidences indicate that the mitochondria
could play a major role (Marchetti et al., 2008; Mulder and
Ling, 2009). In fact, the activities of the mitochondrial enzymes
glycerol phosphate dehydrogenase, pyruvate carboxylase and
succinyl-CoA:3-ketoacid-CoA transferase have been reported to
be ∼65–90% lower in the diabetic compared with control islets
(MacDonald et al., 2009). Furthermore, ATP citrate lyase, a
cytosolic enzyme involved in the mitochondrial citrate pyruvate
shuttle, was also reduced of more than 50% (MacDonald et al.,
2009). All this could explain, at least in part, the observation that
glucose oxidation is reduced in T2D (Del Guerra et al., 2005).
In addition, T2D beta cell mitochondria look round shaped and
with lower density by electron microscopy analysis, and when
adenine nucleotide content was quantified, it was observed that
cells from T2D subjects did not increase their ATP content
upon acute glucose stimulation (Anello et al., 2005). Hence, the
ATP/ADP ratio was almost 50% lower in T2D than control islets,
and, accordingly, altered hyperpolarization of the mitochondrial
membrane, as well as augmented expression of UCP-2, complex
I, and complex V of the respiratory chain were observed (Anello
et al., 2005). On top of all this, a more general defect contributing
to defective insulin secretion in T2D beta cells could be the
reduced expression of molecules involved in insulin granule
exocytosis, such as those of the SNARE complex and SNARE-
modulating proteins (syntaxin-1A, SNAP-25, VAMP-2, Munc 18,
Munc 13-1, and synaptophysin; Ostenson et al., 2006).
Finally, insulin release from T2D beta cells has been reported
to show alterations of the pulsed pattern (Lin et al., 2002), and it is
associated with the release of four- to five-fold higher proportions
of proinsulin, indicating less efficient conversion of proinsulin to
insulin (Cavaghan and Polonsky, 2005; Henquin, 2005; Marchetti
and Ferrannini, 2015).
Therefore, the functional identity of the beta cell is
indissolubly linked to its capacity to secrete insulin in response
to increased glucose levels, which is regulated by several
intracellular organelles and mechanisms and whose impairment
is the hallmark of type 2 diabetes.
ULTRASTRUCTURAL IDENTITY
At the ultrastructural level, beta cells are identified by the
presence of the typical insulin granules (Lacy and Hartroft, 1959;
Orci, 1985; In’t Veld and Marichal, 2010; Ivanova et al., 2013).
Insulin granules are characterized by an electron dense core and
a clear peripheral mantle (Figure 2A), their size is around 300 nm
and their number has been estimated to be∼10,000 per beta cell.
Depending on the level of maturation, the mantle of the granules
may contain proinsulin that is not yet fully processed; when the
cleavage of this precursor is unsufficient, the dense core may
be absent and typical immature “gray” granules may be found
(In’t Veld and Marichal, 2010; Masini et al., 2012) (Figure 2B).
Interestingly, a proportion of insulin granules is located in close
proximity of the cell membrane (Ohara-Imaizumi et al., 2004;
Masini et al., 2012), representing a population defined as “docked
granules” (Figure 2C), possibly involved in the first phase of
insulin release. Several changes at the level of insulin granules
have been reported in T2D islet beta cells (Marchetti et al.,
2004; Masini et al., 2012). In fact, the overall amount of insulin
granules is lower in the T2D diabetic beta cells (Marchetti et al.,
2004; Masini et al., 2012); in addition, the proportion of mature
“docked” granules is also lower in ND compared to T2D beta cells
(Masini et al., 2012).
Further ultrastructural changes that occur in T2D beta cells
involve the mitochondria and the endoplasmic reticulum (ER)
(Anello et al., 2005; Marchetti et al., 2007). As mentioned above,
mitochondrial dysfunction is likely to play a major role in
impaired glucose-stimulated insulin release from T2D beta cells;
this is accompanied by changes in the morphology of these
organelles, that look round-shaped rather than elongated, with
alterations in cristae appearance, reduced electron density and
augmented overall volume (Figures 2D,E; Anello et al., 2005). In
turn, the ER is usually more readily visible in T2D than ND beta
cells (Figure 2F), showing concentrically arranged, not dilated
cisternae and strongly electron-dense ribosomes bound to the
membranes (Marchetti et al., 2007); when quantified, ER volume
density in T2D beta cells was found to be two-fold higher than
that of control beta cells (Marchetti et al., 2007).
Although, possibly over-estimated (Marselli et al., 2014), beta
cell death can contribute to the loss of beta cell functional mass
in T2D (Cnop et al., 2005; Laybutt et al., 2007; Marchetti et al.,
2008). In fact, the amount of apoptotic beta cells is increased in
T2D islets (Cnop et al., 2005; Laybutt et al., 2007; Marchetti et al.,
2008). Typically, when compared to a normal beta cell, at the EM
an apoptotic beta cell show alterations such as marked chromatin
condensation in the nucleus (Figures 3A,B), membrane bledding
and apoptotic bodies (Galluzzi et al., 2009). However, other
mechanisms may lead to beta cell death, including those
associated with dysregulated autophagy (Masini et al., 2009;
Watada and Fujitani, 2015): in this case, the beta cells show
massive accumulation of vacuoles characterized by the presence
of close double membranes surrounding organelles and/or
cytoplasmic portions, in the absence of nuclear abnormalities
(Figure 3C).
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FIGURE 2 | Electron microscopy images of non-diabetic (ND) and type 2 diabetic (T2D) beta cells. (A) Insulin granules in an ND beta cell, with their typical
ultrastructure; (B) mature (MG) and immature (IG) insulin granule in an ND beta cell; (C) docked insulin granules (arrows indicate the beta cell membrane);
(D) mitochondria (white arrows) in an ND beta cell (gray arrows indicate insulin granules); (E) mitochondria (white arrows) in a T2D beta cell (gray arrows indicate insulin
granules); (F) endoplasmic reticulum (RER) in a T2D beta cell (the RER is usually barely detectable in ND beta cells—see panel A) N, Nucleus. Reproduced with
permission from Anello et al. (2005) and Masini et al. (2012).
FIGURE 3 | (A) A normal beta cell (N, nucleus; IG, insulin granules); (B) a beta cell with apoptotic nucleus (CC, chromatin condensation; IG, insulin granules); (C) a
beta cell with signs of death associated with dysregulated autophagy (massive vacuole accumulation in the cytoplasm; N, nucleus; IG, insulin granules). Reproduced
with permission from Marchetti et al. (2007) and Masini et al. (2009).
In summary, the T2D diabetic beta cells show
several ultrastructural alterations in different intracellular
compartments; although not fully pathognomonic of the diabetic
condition, these changes allow inferences on the organelles and
mechanisms involved in beta cell functional and survival defects.
CONCLUSIONS
Pancreatic beta cells uniquely synthetize, store, and release
insulin. Specificmolecular, functional and ultrastructural features
characterize these cells and their insulin secretion activity
as well as survival properties. Several changes occur in
type 2 diabetic beta cells, playing roles in the disease and
representing possible targets for therapeutical interventions.
However, the pathophysiological interplay between many
different mechanisms and pathways does not allow, presently,
to identify single culprits associated with the presence of type 2
diabetes. This complex scenario needs further and, at the same
time, more comprehensive and fine approaches to better describe
the trajectory of beta cell phenotype in the onset and progression
of type 2 diabetes.
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